Compare AKBA & FUBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | FUBO |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 256.4M |
| IPO Year | 2014 | 2011 |
| Metric | AKBA | FUBO |
|---|---|---|
| Price | $1.23 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.67 | ★ $20.33 |
| AVG Volume (30 Days) | ★ 4.1M | 1.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,271,000.00 |
| Revenue This Year | N/A | $44.64 |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10317.07 |
| 52 Week Low | $0.82 | $1.02 |
| 52 Week High | $3.81 | $14.54 |
| Indicator | AKBA | FUBO |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 39.27 |
| Support Level | $1.16 | $7.95 |
| Resistance Level | $1.52 | $10.69 |
| Average True Range (ATR) | 0.07 | 0.60 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 7.59 | 0.88 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
FuboTV Inc is a sports-first, Pay TV replacement product offering subscribers access to tens of thousands of live sporting events annually, alongside news and entertainment content, both live and on demand. Its platform is designed to empower customers to seamlessly access content through streaming devices and on Smart TVs, mobile phones, tablets, and computers. The company offers subscribers a live TV streaming service with the option to purchase incremental features, including additional content or enhanced functionality suited to their preferences. Its subscription packages (including Fubo Essential, Pro, Elite, and others) boast a broad mix of top Nielsen-ranked channels across sports, news, and entertainment. It operates in a single segment of the streaming business.